involving stage III/IV NSCLC patients with EGFR/anaplastic lymphoma kinase (ALK)-wild-type, the combination of MWA and camrelizumab was reported to be safe and effective (94). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.